Complete Rejection Of Established Triple Negative Breast Cancer By Local Immunochemotherapy Through Activation Of Anti-tumor Immunity

Cancer immunotherapies,including immune checkpoint blockage(ICB)and adoptive transfer of CAR-T cells,have achieved historical successes for many kinds of malignancy.However,a minority of patients survive long-term over 5 years without relapse,perhaps owing to tumor heterogeneity and potent immunosuppression in the tumor microenvironment.Here,using an established mouse tumor model of triple-negative 4T1 breast cancer,we show that local immunochemotherapy triggers powerful local and systemic antitumor immunity.Paraneoplastic injection of Cp G,a-OX40,and anthracycline(ADM)completely eliminated both local and distant large established 4T1 breast cancer without obvious relapse.Analysis of the immune cells at tumor tissues,draining lymph nodes,and spleens revealed that the local treatment increased the infiltration of CD4~+and CD8~+T cells in all three tissues,and inhibited the accumulation of myeloid-derived suppressor cells(MDSCs)in the spleen in a delayed response.Most importantly,this treatment triggered systemic T cell response against 4T1 tumors and some of their neoantigen epitopes as detected by IFN-Υ ELISpot and intracellular cytokine staining assays in splenocytes.Furthermore,T cells showed specific cytotoxic activity against 4T1 tumor cells in vitro.In general,this local immunochemotherapy provides a new approach to target highly diverse neoantigens in various types of cancers without complicated and expensive antigen identification via next-generation sequencing.